A 62-year-old man from Delhi presents with a 3-year history of progressive tremor at rest, rigidity, and bradykinesia. He was started on levodopa-carbidopa 6 months ago with good initial response, but now complains of involuntary choreiform movements of the limbs and face that appear 2–3 hours after each dose and resolve before the next dose. His wife reports he also has unpredictable episodes of sudden immobility lasting 30 seconds to 2 minutes. On examination, he has obvious dyskinesias during the "on" phase. Serum electrolytes and renal function are normal. Which of the following best explains the mechanism underlying his involuntary movements?

Explanation

## Mechanism of Levodopa-Induced Dyskinesias (LID) **Key Point:** Levodopa-induced dyskinesias are a consequence of pulsatile dopamine receptor stimulation in a denervated striatum, not toxicity or immune phenomena. ### Pathophysiology In Parkinson's disease, progressive loss of dopaminergic neurons (>70% depletion at symptom onset) means the striatum loses its capacity for tonic dopamine buffering. When levodopa is given orally, it produces **pulsatile peaks and troughs** in striatal dopamine concentration rather than the physiologic steady-state seen in healthy brains. 1. **Receptor sensitization**: Chronic pulsatile stimulation causes upregulation and altered sensitivity of D1 and D2 receptors on medium spiny neurons. 2. **Altered intracellular signaling**: Dyskinesias correlate with abnormal phosphorylation of DARPP-32 (dopamine- and cAMP-regulated phosphoprotein) and altered gene expression (ΔFosB accumulation). 3. **Loss of buffering**: Intact dopaminergic terminals normally smooth out dopamine fluctuations; in Parkinson's disease, this capacity is lost. 4. **Timing**: Dyskinesias typically emerge 4–6 years after levodopa initiation and correlate with the degree of dopaminergic denervation and pulsatility of drug exposure. **High-Yield:** The "on-off" dyskinesias (choreiform movements during high dopamine levels) and "off" freezing episodes (sudden immobility during low dopamine) both reflect the same underlying problem: loss of striatal dopaminergic buffering capacity. ### Clinical Correlates **Clinical Pearl:** Strategies to reduce pulsatility—such as continuous dopaminergic stimulation (extended-release formulations, dopamine agonists, COMT inhibitors, MAO-B inhibitors, or apomorphine infusions)—can delay or reduce dyskinesia severity. **Mnemonic:** **PULSATILE = Parkinson's Unilateral Loss of Steady dopamine = Involuntary movements, dyskinesias, Emergent** ### Why This Patient's Presentation Fits - 3-year levodopa exposure → sufficient time for sensitization - Dyskinesias appear in the "on" phase (peak dopamine) → pulsatile effect - "Off" freezing episodes → loss of tonic dopaminergic tone - Normal renal function and electrolytes → no metabolic cause [cite:KD Tripathi 8e Ch 12]